Emily Luisa Hill
Net Worth
Last updated:
What is Emily Luisa Hill net worth?
The estimated net worth of Ms. Emily Luisa Hill is at least $6,736,699 as of 27 Mar 2023. She owns shares worth $1,911,607 as insider, has earned $912,592 from insider trading and has received compensation worth at least $3,912,500 in PTC Therapeutics, Inc..
What is the salary of Emily Luisa Hill?
Ms. Emily Luisa Hill salary is $782,500 per year as Chief Financial Officer in PTC Therapeutics, Inc..
How old is Emily Luisa Hill?
Ms. Emily Luisa Hill is 44 years old, born in 1981.
What stocks does Emily Luisa Hill currently own?
As insider, Ms. Emily Luisa Hill owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| PTC Therapeutics, Inc. (PTCT) | Chief Financial Officer | 38,925 | $49.11 | $1,911,607 |
What does PTC Therapeutics, Inc. do?
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Emily Luisa Hill insider trading
PTC Therapeutics, Inc.
Ms. Emily Luisa Hill has made 19 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently she sold 7,363 units of PTCT stock worth $331,335 on 27 Mar 2023.
The largest trade she's ever made was exercising 26,033 units of PTCT stock on 8 Jan 2021. As of 27 Mar 2023 she still owns at least 38,925 units of PTCT stock.
PTC Therapeutics key executives
PTC Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Allan Steven Jacobson (79) Independent Co-Founder, Chairman of Scientific Advisory Board & Director
- Dr. Neil Almstead (58) Chief Technical Operations Officer
- Dr. Stuart W. Peltz (65) Co-Founder, Chief Executive Officer & Executive Director
- Mr. Eric Pauwels (63) Chief Bus. Officer
- Mr. Mark Elliott Boulding (64) Executive Vice President & Chief Legal Officer
- Ms. Emily Luisa Hill (44) Chief Financial Officer